Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $2.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, November 24th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics presently has a consensus rating of “Buy” and an average price target of $4.67.

Lineage Cell Therapeutics Trading Down 1.8%

LCTX stock opened at $1.67 on Monday. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.55. Lineage Cell Therapeutics has a 12 month low of $0.37 and a 12 month high of $2.09. The stock has a market capitalization of $384.65 million, a P/E ratio of -5.76 and a beta of 1.80.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Lineage Cell Therapeutics during the 4th quarter valued at $25,000. Integrity Alliance LLC. raised its position in shares of Lineage Cell Therapeutics by 75.0% in the second quarter. Integrity Alliance LLC. now owns 35,000 shares of the company’s stock worth $32,000 after buying an additional 15,000 shares in the last quarter. Citizens Financial Group Inc. RI bought a new stake in Lineage Cell Therapeutics during the third quarter valued at $25,000. Red Crane Wealth Management LLC grew its position in Lineage Cell Therapeutics by 3.1% during the third quarter. Red Crane Wealth Management LLC now owns 511,363 shares of the company’s stock worth $864,000 after buying an additional 15,365 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after acquiring an additional 18,092 shares during the last quarter. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.